BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lexicon Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Lexicon Pharmaceuticals's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06481891-314@assetmemo.bio
DTSTAMP:20261121T005710Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06481891)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Hypertrophic Cardiomyopathy.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Sotagliflozin in S
 ymptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06481891
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
